USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PROTHERA BIOLOGICS, LLC
Address:
551 Warren Avenue
EAST PROVIDENCE, RI
Phone:
N/A
URL:
N/A
EIN:
710868235
DUNS:
140315248
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,082,857.00 5
SBIR Phase II $1,501,415.00 1
STTR Phase I $1,000,000.00 1
STTR Phase II $2,679,882.00 1

Award List:

THERAPEUTIC USE OF INTER-ALPHA INHIBITOR IN SEPSIS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$143,105.00
Agency:
HHS
Principal Investigator:
Abstract:
The primary goal of this proposed research is targeted towards demonstrating the commercial utilization of human plasma derived inter- alpha inhibitor proteins (IaIp) an effective therapy of sepsis. IaIp are serine protease inhibitors found normally at high levels in human plasma. The fact that no… More

Predictive value of inter-alpha inhibitors in sepsis

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$131,233.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor as a novel predictive marker for adult and newborn sepsis. IaIp are natural serine protease inhibitors found in relatively high concentration in human adult… More

THERAPEUTIC USE OF INTER-ALPHA INHIBITOR IN SEPSIS

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$1,501,415.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of the proposed research is to demonstrate that Inter-alpha serine protease inhibitor proteins (IaIp) are an effective therapy for sepsis. In sepsis, normally high plasma levels of IaIp drop dramatically in adult and newborn patients. We hypothesize… More

Inter-alpha Inhibitors in Detecting CNS Cancer

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$139,911.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant) The overall goal is to develop a marketable novel predictive marker based on inter-alpha inhibitor proteins (laIp) in cerebrospinal fluid (CSF) that can be utilized in the management of CNS cancer. Cost effective care, successful palliation of symptoms and new… More

Role of Inter-alpha Inhibitors in Anthrax Intoxication

Award Year / Program / Phase:
2006 / STTR / Phase I
Award Amount:
$1,000,000.00
Agency:
HHS
Principal Investigator:
Research Institution:
MEMORIAL HOSPITAL OF RHODE ISLAND
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor proteins (lalp) as an effective protective agent against exposure to anthrax, a lethal biological warfare agent. Inter-alpha inhibitor proteins are natural… More

Bioprocessing of Plasma Therapeutic Proteins using Sequential Affinity Monolithic

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$170,547.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Plasma fractionation is one of the largest industry segments in global therapeutic protein manufacture. The United States plays an important role in this industry since it represents the largest plasma collection and ma nufacturing base that accounts for more… More

Role of Inter-alpha Inhibitors in Anthrax Intoxication

Award Year / Program / Phase:
2010 / STTR / Phase II
Award Amount:
$2,679,882.00
Agency:
HHS
Principal Investigator:
Steven M. Opal – 401-729-2545
Research Institution:
Memorial Hospital Of Rhode Island
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Anthrax is recognized as a class A bio-threat microbial pathogen that is readily weaponized and exceedingly difficult to treat. This bacterium is highly virulent inducing lethal infection in immunologically normal hostsby its intrinsic capacity to disseminate… More

Rapid detection of neonatal sepsis

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$498,061.00
Agency:
HHS
Principal Investigator:
Yow-pin Lim – 401-301-2046
Abstract:
DESCRIPTION (provided by applicant): The primary goal of this proposed research is to develop a rapid point-of-care (POC) test that can be used to identify neonatal sepsis in high-risk infants in a simple, user-friendly and portable device suitable for usein the NICU setting. Since sepsis presents a… More